Hepatitis C virus inhibitors

US7906655B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Makonen Belema · North Haven, US
• Andrew C. Good · Wallingford, US
• Jason Goodrich · Meriden, US
• Ramesh Kakarla · Doylestown, US
• Guo Li · Chengdu, CN
• Omar D. Lopez · Wallingford, US
• Van N. Nguyen · West Haven, US
• Jayne Kapur · Houston, US
• Yuping Qiu · Princeton Junction, US
• Jeffrey Lee Romine · Meriden, US
• Denis R. St. Laurent · Newington, US
• Michael H. Serrano-Wu · Cambridge, US
• Lawrence B. Snyder · Killingworth, US
• Fukang Yang · Madison, US

Key dates

• Filing date: Aug 5, 2009
• Grant date: Mar 15, 2011
• Expiry date: Aug 5, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.